KPTI - Karyopharm completes patient recruitment in late-stage selinexor study in endometrial cancer

Karyopharm Therapeutics (NASDAQ:KPTI) announces the completion of patient recruitment in Phase 3 SIENDO study evaluating the efficacy and safety for front-line maintenance therapy with selinexor in patients with advanced or recurrent endometrial cancer. Top-line data from this event-driven study are anticipated by the end of this year or early next year. The SIENDO study has exceeded its enrollment goal, with over 250 patients currently enrolled or in screening. The primary endpoint is progression free survival with the goal of the study demonstrating a hazard ratio of 0.6.

For further details see:

Karyopharm completes patient recruitment in late-stage selinexor study in endometrial cancer